Dr. Perla Lansang

Dermatologist, Toronto, ON

Dr. Perla Lansang is a full-time staff dermatologist and associate professor in the Division of Dermatology, University of Toronto where she is the Division Head of Dermatology at Sunnybrook Health Sciences Centre. She is also cross appointed at the Section of Paediatric Dermatology at the Hospital for Sick Children, and the Division of Obstetric Medicine at Sunnybrook Health Sciences Centre.
She completed her medical school and dermatology residency at the University of the Philippines-Philippine General Hospital. Having done fellowships in paediatric dermatology at The Hospital for Sick Children and in advanced medical dermatology at Sunnybrook Health Sciences Centre, Dr. Lansang’s practice is a mixture of pediatric, adolescent, and adult dermatology, with a special focus on psoriasis, atopic dermatitis, cutaneous lymphoma, pregnancy dermatoses, and general medical dermatology. She has a special interest in immune-mediated skin diseases and has extensive clinical and research experience in many areas of immunodermatology.

10:00 AM - 10:45 AM Open Session

Friday NOV 25, 2022

Deucravacitinib Open Session: PsO Who Are You?

Learning Objectives:

  1. Differentiate TYK2 inhibitors from JAK inhibitors
  2. Identify patients with moderate-to-severe psoriasis who are candidates for oral TYK2 inhibitors based on their disease characteristics and medical history
  3. Apply practical skills to managing patients on TYK2 inhibitors

Summary:
PsO Who Are You is the extraordinary dermatology conference challenge that provides compelling education for all dermatologists!
THE OBJECT OF THE GAME is to discover the answer to three questions related to the use of existing and emerging oral therapies:
WHO are the patients using oral systemic therapies?
WHAT is their medical and treatment history prior to starting an oral therapy?
WHY is an oral therapeutic an appropriate option for those patients?
THE GAME BOARD features three stellar dermatologists: Dr. David Adam, Dr. Perla Lansang, and Dr. Julien Ringuet. Of the many possible patient scenarios, each opponent will present one character who is eligible for advanced oral therapies.
THE GAME PLAY will begin with each opponent taking turns posing questions on medical history and treatment considerations in order to reveal the details of the patient case.
THE GAME ENDS when one opponent correctly guess the patient description based on the clues given throughout the presentation.
Three dermatologists, three patient profiles. Let the game begin!

2:30 PM - 3:15 PM Open Session

Friday NOV 25, 2022

Master the New JAK Inhibitors for Moderate to Severe Atopic Dermatitis

Learning Objectives:

  1. Review the evidence supporting the use of JAK inhibitors in patients with moderate to severe atopic dermatitis
  2. Define the role of JAK inhibitors to address unmet needs in the treatment of moderate to severe atopic dermatitis
  3. Gain knowledge on the use of JAK inhibitors through tips and frequently asked questions (FAQs)

11:15 AM - 12:00 PM Open Session

Saturday NOV 26, 2022

Pso Let’s Talk: “The Trouble with Topicals"

Chronic plaque psoriasis (PsO) is an auto-immune mediated inflammatory skin diseases that varies in severity affecting over 1 million people in Canada.1 The majority of patients present with mild to moderate disease as determined by objective measures used by clinicians, but it is increasingly recognized, disease severity experienced by the patient is more than just a body surface area or PASI score calculation as evidenced by decreased quality of life and higher risks for depression, anxiety and suicide.1,2,3 Although topical corticosteroids (TCSs) remain the foundation of treatment and are used across the spectrum of plaque PsO, there has been a paucity of clinical innovation in comparison to the advances in biologic therapies made in the past decade.3,4

 

Despite good treatment responses with TCSs, they can be limited for long-term use due to local (e.g., stria, skin atrophy, and telangiectasia) or systemic (e.g., hypothalamic-pituitary-adrenal [HPA] axis suppression) adverse events (AEs).5 Topical retinoids and vitamin D analogs, originally introduced in the latter part of the 20th century, have their own troublesome AEs with skin irritation (e.g., redness, itching, stinging or burning, peeling and dryness) as a common cause for a patients’ dissatisfaction and/or lack of adherence.3,5 Topical calcineurin inhibitors and the only currently available topical phosphodiesterase- 4 inhibitor in Canada, are indicated for atopic dermatitis, but have been used for PsO with some success in the sensitive intertriginous and facial areas.6 There is limited access for these latter drugs depending on patients’ private insurance coverage.

 

PsO is a heterogeneous disease with varied clinical presentations with almost 90% of patients experiencing PsO in more than one location.4,6 Due to the limitations of today’s topical armamentarium, dermatologists often need to prescribe during one patient visit 2 or 3 different topicals of varying potencies and/or formulations. This can be troublesome for patients as they tend to forget or misunderstood the instructions provided by their dermatologist which can be confounded by further troubling instructions from the dispensing pharmacist.3,4 As such, the trouble with topicals today remains and there continues a large unmet need to develop a simplified regimen that is better tolerated with a cosmetically pleasing formulation which is steroid-sparing yet has a fast onset of action with an effectiveness comparable to mid-high potency TCSs. The trek towards this goal will be explored as new developments in topical non-steroid therapy will be presented.